Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.
Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, Karimi M, Bengtzén S, Nahi H, Uggla B, Tidefelt U, Höglund M, Paul C, Ekwall K, Döhner K, Lehmann S. Deneberg S, et al. Among authors: blanchet o. Blood. 2011 Nov 17;118(20):5573-82. doi: 10.1182/blood-2011-01-332353. Epub 2011 Sep 29. Blood. 2011. PMID: 21960591 Free article.
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Tamburini J, et al. Among authors: blanchet o. Blood. 2007 Aug 1;110(3):1025-8. doi: 10.1182/blood-2006-12-061283. Epub 2007 Apr 10. Blood. 2007. PMID: 17426258 Free article. Clinical Trial.
Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples.
de la Blétière DR, Blanchet O, Cornillet-Lefèbvre P, Coutolleau A, Baranger L, Geneviève F, Luquet I, Hunault-Berger M, Beucher A, Schmidt-Tanguy A, Zandecki M, Delneste Y, Ifrah N, Guardiola P. de la Blétière DR, et al. Among authors: blanchet o. BMC Med Genomics. 2012 Jan 30;5:6. doi: 10.1186/1755-8794-5-6. BMC Med Genomics. 2012. PMID: 22289410 Free PMC article.
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.
Lioure B, Béné MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, Blaise D, Witz B, Delain M, Cornillon J, Luquet I, Blanchet O, Cornillet-Lefebvre P, Carré M, Hunault M, Larosa F, Lamy T, Randriamalala E, Ojeda-Uribe M, Berthou C, Fornecker L, Harousseau JL, Bouscary D, Ifrah N, Cahn JY; GOELAMS. Lioure B, et al. Among authors: blanchet o. Blood. 2012 Mar 22;119(12):2943-8. doi: 10.1182/blood-2011-05-352989. Epub 2012 Feb 9. Blood. 2012. PMID: 22323482 Free article. Clinical Trial.
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H; French AML Intergroup. Jourdan E, et al. Among authors: blanchet o. Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15. Blood. 2013. PMID: 23321257 Free article. Clinical Trial.
Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis.
Luque Paz D, Boyer F, Beucher A, Bouvier A, Jouanneau-Courville R, Guardiola P, Lambert D, Delneste Y, Hunault M, Blanchet O, Ugo V. Luque Paz D, et al. Among authors: blanchet o. Blood Cells Mol Dis. 2018 Jul;71:75-76. doi: 10.1016/j.bcmd.2018.04.002. Epub 2018 Apr 23. Blood Cells Mol Dis. 2018. PMID: 29703677 No abstract available.
Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial.
Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Béné MC, Ifrah N; GOELAMS (Groupe Ouest-Est des Leucémies Airguës et Maladies du Sang) Group. Hunault M, et al. Among authors: blanchet o. Blood. 2004 Nov 15;104(10):3028-37. doi: 10.1182/blood-2003-10-3560. Epub 2004 Jul 15. Blood. 2004. PMID: 15256423 Free article. Clinical Trial.
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.
Bertoli S, Bories P, Béné MC, Daliphard S, Lioure B, Pigneux A, Vey N, Delaunay J, Leymarie V, Luquet I, Blanchet O, Cornillet-Lefebvre P, Hunault M, Bouscary D, Fegueux N, Guardiola P, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Récher C; Groupe Ouest-Est d’Etude des Leucémies Aiguës et Autres Maladies du Sang (GOELAMS). Bertoli S, et al. Among authors: blanchet o. Haematologica. 2014 Jan;99(1):46-53. doi: 10.3324/haematol.2013.091819. Epub 2013 Aug 23. Haematologica. 2014. PMID: 23975179 Free PMC article. Clinical Trial.
Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS. Guièze R, et al. Among authors: blanchet o. Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22. Am J Hematol. 2012. PMID: 22911473 Free article. Clinical Trial.
80 results